Sugi Predict

Sugi Predict / Compounds / SCHEMBL735799

SCHEMBL735799

SCHEMBL735799

O=C(NCC[C@@H](O)C(=O)O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 1/20 0.64
▸ SLC1A1 P43005 1/20 0.64
▸ LMNA P02545 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ HTT P42858 1/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ FOLH1 Q04609 4/20 0.54
▸ TGM2 P21980 1/20 0.53
▸ KEAP1 Q14145 2/20 0.52
▸ NFE2L2 Q16236 2/20 0.52
▸ MAPT P10636 1/20 0.51
▸ MMP2 P08253 1/20 0.51
▸ MMP9 P14780 1/20 0.51
▸ DPP8 Q6V1X1 1/20 0.49
▸ DPP7 Q9UHL4 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334926 1.00 SLC1A3 (0.64) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL334927 1.00 SLC1A3 (0.64) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL2139878 0.91 HTT (0.65) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL2139876 0.91 HTT (0.65) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL11317170 0.91 HTT (0.65) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL6827224 0.90 HTT (0.63) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL318936 0.90 HTT (0.63) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL318935 0.90 HTT (0.63) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL6827355 0.89 TGM2 (0.62) SLC1A3SLC1A1LMNASMN1; SMN2HTT
SCHEMBL6827174 0.89 TGM2 (0.62) SLC1A3SLC1A1LMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932633-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2024-03-19 — — US disclosed
US-20210380570-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2021-12-09 — — US disclosed
EP-3790551-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-17 — — EP disclosed
WO-2019217307-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-11-14 — — WO disclosed
US-20160152653-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS MEIJI SEIKA PHARMA CO LTD (JP) 2016-06-02 — — US disclosed
US-9260465-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-02-16 — — US disclosed
CN-102942603-B New aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-20 — — CN disclosed
EP-2036917-B1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC MEIJI SEIKA PHARMA CO LTD (JP) 2015-10-07 — — EP disclosed
US-20130345411-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2013-12-26 — — US disclosed
US-8541394-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2013-09-24 — — US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 — — EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 — — WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 — — US disclosed
US-20090186841-A1 Novel aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-07-23 — — US disclosed
EP-2036917-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC MEIJI SEIKA KAISHA LTD. (JP) 2009-03-18 — — EP disclosed
US-6033882-A DERIVED FROM LACTOBACILLUS DELBRUECKII SSP. BULGARICUS. GENZYME CORPORATION (US) 2000-03-07 — — US disclosed
EP-0767832-A1 CHIRAL SYNTHESIS OF 2-HYDROXY CARBOXYLIC ACIDS WITH A DEHYDROGENASE Genzyme Limited (GB) 1997-04-16 — — EP disclosed
WO-1996001892-A1 CHIRAL SYNTHESIS OF 2-HYDROXY CARBOXYLIC ACIDS WITH A DEHYDROGENASE GENZYME LIMITED (GB) 1996-01-25 — — WO disclosed
US-4231945-A BACTERICIDES SCHERING CORPORATION (US) 1980-11-04 — — US disclosed
US-4212860-A COUPLING THE PENTOFURANOSYL ONTO THE PROTECTED CYCLITOL SCHERING CORPORATION (US) 1980-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345411-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS ATP6V1B1, REN, NRDC SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885
US-20210380570-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS SLC1A3 3382/4885SLC1A1 3969/4885LMNA 2991/4885
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 SLC1A3 1680/4885SLC1A1 1225/4885LMNA 3760/4885
US-20160152653-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS ATP6V1B1, REN, NRDC SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885
US-20090186841-A1 Novel aminoglycoside antibiotics ATP6V1B1, REN, NRDC SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885
US-11932633-B2 KRas G12C inhibitors KRAS, NRAS, HRAS SLC1A3 3382/4885SLC1A1 3969/4885LMNA 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.